ClearPoint Neuro, Inc.
No enriched coverage for $CLPT in the last 7 days.
No SEC Form 4 filings for $CLPT in the last 30 days.
See all $CLPT insider activity →ClearPoint Neuro (CLPT) shares dropped 24% after partner uniQure (QURE) reported disappointing trial data for its Huntington's disease treatment, AMT-130. The therapy failed to meet primary clinical measures, raising concerns about future revenue for ClearPoint Neuro, which provides delivery hardware and software for the treatment.
ClearPoint Neuro, Inc. (NASDAQ:CLPT) reported Q2 results that missed expectations. According to the article, revenue was $11m, 15% below forecasts, and statutory losses rose 33% to $0.38 per share. For 2026, three analysts’ consensus estimates were cut to $48.9m revenue and $1.32 loss per share, while the consensus price target fell 9.4% to $25.67.
Powell Industries reported Q3 EPS of $1.42, below the $1.47 analyst consensus, and sales of $312.0 million, below the $315.168 million estimate, according to the company. Shares fell 13.4% to $190.02 in pre-market trading. The article also notes Nasdaq 100 futures were up about 150 points.
Recent CLPT coverage spans earnings, market movers and financial news.
ClearPoint Neuro likely faces near‑term sell pressure as its commercial upside from the uniQure partnership is called into question.
Analyst consensus for 2026 shifts lower on both revenue and profitability, with the consensus price target dropping 9.4%.
Powell Industries reported Q3 EPS of $1.42, below the $1.47 analyst consensus, and sales of $312.0 million, below the $315.168 million estimate, according to the company. Shares fell 13.4% to $190.02 in pre-market trading. The article also notes Nasdaq 100 futures were up about 150 points.
Guidance reset plus progress signals (FDA feedback to partners, CAL GLP statement of work, focused ultrasound partnership) can re-rate near-term expectations for commercial readiness and trial-driven demand.
RMAT designation is a positive regulatory-development signal for Aspen’s PD cell therapy, indirectly supporting ClearPoint’s trial participation narrative and partner momentum.
AlphAI scores every news story that mentions CLPT with an AI model for sentiment and relevance, and aggregates insider trades from ClearPoint Neuro, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
ClearPoint Neuro (CLPT) shares dropped 24% after partner uniQure (QURE) reported disappointing trial data for its Huntington's disease treatment, AMT-130. The therapy failed to meet primary clinical measures, raising concerns about future revenue for ClearPoint Neuro, which provides delivery hardware and software for the treatment.
2 min readClearPoint Neuro, Inc. (NASDAQ:CLPT) reported Q2 results that missed expectations. According to the article, revenue was $11m, 15% below forecasts, and statutory losses rose 33% to $0.38 per share. For 2026, three analysts’ consensus estimates were cut to $48.9m revenue and $1.32 loss per share, while the consensus price target fell 9.4% to $25.67.
5 min readPowell Industries reported Q3 EPS of $1.42, below the $1.47 analyst consensus, and sales of $312.0 million, below the $315.168 million estimate, according to the company. Shares fell 13.4% to $190.02 in pre-market trading. The article also notes Nasdaq 100 futures were up about 150 points.
1 min readClearPoint Neuro, Inc. (CLPT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ClearPoint Neuro Reports Second Quarter 2026 Results Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA, August 3, 2026 – ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a globa
6 min readClearPoint Neuro (Nasdaq:CLPT) said the FDA granted Aspen Neuroscience RMAT designation for sasineprocel (ANPD001), an investigational autologous dopaminergic neuron cell therapy for Parkinson’s disease. ClearPoint noted its ClearPoint Neuro Navigation System and SmartFlow Cannula were used in Aspen’s ASPIRO trial. RMAT provides expedited FDA interactions but is not FDA approval.
4 min readClearPoint Neuro, Inc. (NASDAQ:CLPT) said it will release its 2026 second-quarter results on August 3, 2026 after the market close. The company will host a live conference call the same day at 4:30 p.m. ET, with a replay available until September 2, 2026. No financial figures were provided.
2 min readBURNETT JOSEPH (CEO and President) sold 60,000 shares of ClearPoint Neuro, Inc. (CLPT) at $17.79 ($1.07M total) on 2026-06-17 under a Rule 10b5-1 trading plan.
2 min readuniQure (QURE) surged 78% after the FDA said the 3-year Phase I/II analysis for AMT-130 in Huntington’s could serve as primary evidence for an accelerated BLA; QURE plans to file in Q3 2026. Elicio (ELTX) rose 71% on Phase 2 AMPLIFY-7P responses. Lunai (LNAI) gained 40% on CEO updates; other biotech movers included CLPT, PLRZ and FTH.
5 min readChunghwa Leading Photonics Tech (CLPT) said it expects about 30% annual revenue growth this year, citing rising demand for optical inspection tools used in advanced chip packaging and AI-driven chip testing. CLPT president Lin Chia-chien said orders for linear sensors will ramp in 2H and photodiodes for laser power meters will also grow. Last year revenue rose 29.8% to NT$257m; EPS increased to NT$6.7. CLPT targets gross margin of 60–70% and plans an Emerging Stock Board debut at NT$120/share.
4 min readKlein Matthew B. sold 16,000 shares of ClearPoint Neuro, Inc. (CLPT) at $11.59 ($0.19M total) on 2026-05-21.
1 min read
